Depression Treatment: Importance of the Brain Angiotensin System in Parkinson’s Disease.

Importance of the brain Angiotensin system in Parkinson’s disease.

Filed under: Depression Treatment

Parkinsons Dis. 2012; 2012: 860923
Wright JW, Harding JW

Parkinson’s disease (PD) has become a major health problem affecting 1.5% of the world’s population over 65 years of age. As life expectancy has increased so has the occurrence of PD. The primary direct consequence of this disease is the loss of dopaminergic (DA) neurons in the substantia nigra and striatum. As the intensity of motor dysfunction increases, the symptomatic triad of bradykinesia, tremors-at-rest, and rigidity occur. Progressive neurodegeneration may also impact non-DA neurotransmitter systems including cholinergic, noradrenergic, and serotonergic, often leading to the development of depression, sleep disturbances, dementia, and autonomic nervous system failure. L-DOPA is the most efficacious oral delivery treatment for controlling motor symptoms; however, this approach is ineffective regarding nonmotor symptoms. New treatment strategies are needed designed to provide neuroprotection and encourage neurogenesis and synaptogenesis to slow or reverse this disease process. The hepatocyte growth factor (HGF)/c-Met receptor system is a member of the growth factor family and has been shown to protect against degeneration of DA neurons in animal models. Recently, small angiotensin-based blood-brain barrier penetrant mimetics have been developed that activate this HGF/c-Met system. These compounds may offer a new and novel approach to the treatment of Parkinson’s disease.
HubMed – depression


Subdural hematoma: an adverse event of electroconvulsive therapy-case report and literature review.

Filed under: Depression Treatment

Case Rep Psychiatry. 2012; 2012: 585303
Kulkarni RR, Melkundi S

Electroconvulsive therapy (ECT) is commonly used in the management of medication nonresponsive depressive disorder, with proven efficacy in psychiatric practice since many decades. A rare complication of intracranial bleed following this therapeutic procedure has been reported in sporadic case reports in the English literature. We report a case of such a complication in a 42-year-old male, a known case of nonorganic medication nonresponsive depressive disorder for the last two years who required ECT application. Presenting symptoms included altered mental state, urinary incontinence, and repeated episodes of vomiting; following ECT procedure with magnetic resonance imaging (MRI) of the brain suggestive of bilateral acute subdural hematoma. Despite the view that it may be used in neurological conditions without raised intracranial tension, it will be worthwhile to be vigilant during post-ECT recovery for any emergent complications.
HubMed – depression


Transient serotonin syndrome by concurrent use of electroconvulsive therapy and selective serotonin reuptake inhibitor: a case report and review of the literature.

Filed under: Depression Treatment

Case Rep Psychiatry. 2012; 2012: 215214
Okamoto N, Sakamoto K, Yamada M

The serotonin syndrome, which is characterized by psychiatric, autonomic nervous and neurological symptoms, is considered to be caused by excessive stimulation of the 5-HT1A and 5-HT2 receptors in the gray matter and spinal cord of the central nervous system, after the start of dosing or increase of the dose of a serotoninergic drug. There have been hardly any reports of induction of serotonin syndrome by electroconvulsive therapy (ECT) in combination with antidepressant. We present the case of a female patient with major depressive disorder (MDD) who developed transient serotonin syndrome soon after the first session of ECT in combination with paroxetine. Paroxetine was discontinued, and her psychiatric, autonomic nervous and neurological symptoms were gradually relieved and disappeared within 2 days. We performed the second ECT session 5 days after the initial session and performed 12 sessions of ECT without any changes in the procedure of ECT and anesthesia, but no symptoms of SS were observed. Finally, her MDD remitted. ECT might cause transiently increased blood-brain barrier (BBB) permeability and enhance the transmissivity of the antidepressant in BBB. Therefore, it is necessary to pay attention to rare side effect of serotonin syndrome by ECT in combination with antidepressant.
HubMed – depression



Cost Effectiveness of Depression Treatment After Acute Coronary Syndrome by Dr. Joseph Ladapo


Treatment for Chronic Depression: Cognitive Behavioral Analysis System of Psycho

End Date: Monday Aug-10-2020 1:09:19 PDT
Buy It Now for only: $39.77
Buy It Now | Add to watch list


Treatment of Recurrent Depression by Greden, John F.
End Date: Saturday Aug-8-2020 3:50:43 PDT
Buy It Now for only: $5.15
Buy It Now | Add to watch list


Depression : Biology, Psychodynamics, and Treatment
End Date: Tuesday Jul-28-2020 6:51:51 PDT
Buy It Now for only: $20.68
Buy It Now | Add to watch list


More Depression Treatment Information…